Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab.
about
A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors.Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies.Phenotyping and Visualizing Infusion-Related Reactions for Breast Cancer Patients.Pertuzumab and trastuzumab infusion related cytokine release syndrome in a chemotherapy naive patient with metastatic breast cancer.
P2860
Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Incidence, risk factors, and m ...... atients receiving trastuzumab.
@en
Incidence, risk factors, and m ...... atients receiving trastuzumab.
@nl
type
label
Incidence, risk factors, and m ...... atients receiving trastuzumab.
@en
Incidence, risk factors, and m ...... atients receiving trastuzumab.
@nl
prefLabel
Incidence, risk factors, and m ...... atients receiving trastuzumab.
@en
Incidence, risk factors, and m ...... atients receiving trastuzumab.
@nl
P2093
P2860
P1433
P1476
Incidence, risk factors, and m ...... patients receiving trastuzumab
@en
P2093
Bonnie L Boster
Chad M Barnett
Gabriel N Hortobágyi
Karen Eckmann
Kenneth R Hess
Laura B Michaud
Lisa M Thompson
P2860
P304
P356
10.1634/THEONCOLOGIST.2013-0286
P577
2014-02-17T00:00:00Z